In the BioHarmony Drug Report Database
Ataluren
Translarna (ataluren) is a small molecule pharmaceutical. Ataluren was first approved as Translarna on 2014-07-31. It has been approved in Europe to treat duchenne muscular dystrophy.
Trade Name
|
Translarna |
|---|---|
Common Name
|
ataluren |
ChEMBL ID
|
CHEMBL256997 |
Indication
|
duchenne muscular dystrophy |
Drug Class
|
Inducers of ribossomal readthrough of nonsense mutation mRNA stop codons |
Image (chem structure or protein)